,terms,label,prediction,extended_terms,extended_prediction
0,placebo group ( n = nmbr ),arms;measures,arms,placebo group ( n = nmbr ),arms
1,warfarin group ( n = nmbr ),arms;measures,arms,warfarin group ( n = nmbr ),arms
6,p value,arms;measures,measures,p value,measures
47,p value for interaction^,arms;measures;p-interaction,measures,p value for interaction^,measures
48,placebo group,arms;measures;p-interaction,arms,placebo group,arms
50,warfarin group,arms;measures;p-interaction,arms,warfarin group,arms
52,hazard ratio ( nmbr % ci ) *,arms;measures;p-interaction,measures,hazard ratio ( nmbr % ci ) *,measures
118,placebo + nmbr mg / d of simvastatin ( n = nmbr ),arms;measures,arms,placebo + nmbr mg / d of simvastatin ( n = nmbr ),arms
119,simvastatin ( nmbr / nmbr mg / d ) ( n = nmbr ),arms;measures,arms,simvastatin ( nmbr / nmbr mg / d ) ( n = nmbr ),arms
175,overall effect,characteristic_name;characteristic_level,characteristic_name,overall effect,characteristic_name
177,males,characteristic_name;characteristic_level,characteristic_name,males,characteristic_name
179,females,characteristic_name;characteristic_level,characteristic_name,females,characteristic_name
181,< nmbr years,characteristic_name;characteristic_level,characteristic_level,< nmbr years,characteristic_level
183,> = nmbr yea ' s,characteristic_name;characteristic_level,characteristic_level,> = nmbr yea ' s,characteristic_level
185,non - diabetics,characteristic_name;characteristic_level,characteristic_level,non - diabetics,characteristic_level
187,diabetics,characteristic_name;characteristic_level,characteristic_name,diabetics,characteristic_name
189,no prior aspirin,characteristic_name;characteristic_level,characteristic_level,no prior aspirin,characteristic_level
191,prior aspirin,characteristic_name;characteristic_level,characteristic_level,prior aspirin,characteristic_level
193,normal troponin,characteristic_name;characteristic_level,characteristic_level,normal troponin,characteristic_level
195,elevated troponin,characteristic_name;characteristic_level,characteristic_name,elevated troponin,characteristic_name
197,no st depression or elevation,characteristic_name;characteristic_level,characteristic_level,no st depression or elevation,characteristic_level
199,st depression or elevation,characteristic_name;characteristic_level,characteristic_name,st depression or elevation,characteristic_name
201,timi risk score nmbr - nmbr,characteristic_name;characteristic_level,characteristic_level,timi risk score nmbr - nmbr,characteristic_level
205,no . of events,measures;p-interaction,measures,no . of events,measures
207,relative risk ( nmbr % confidence interval ),measures;p-interaction,characteristic_level,relative risk ( nmbr % confidence interval ),characteristic_level
208,p value,measures;p-interaction,measures,p value,measures
217,p for interaction,measures;p-interaction,measures,p for interaction,measures
306,mean ( sd ),characteristic_name;characteristic_level,characteristic_level,mean ( sd ),characteristic_level
310,nmbr - nmbr,characteristic_name;characteristic_level,characteristic_level,nmbr - nmbr,characteristic_level
317,> nmbr,characteristic_name;characteristic_level,characteristic_level,> nmbr,characteristic_level
320,current,characteristic_name;characteristic_level,characteristic_level,current,characteristic_level
324,past or never,characteristic_name;characteristic_level,characteristic_level,past or never,characteristic_level
327,never / rarely,characteristic_name;characteristic_level,characteristic_level,never / rarely,characteristic_level
331,at least nmbr / mo,characteristic_name;characteristic_level,characteristic_level,at least nmbr / mo,characteristic_level
334,multivitamin use,characteristic_name;characteristic_level,characteristic_name,multivitamin use,characteristic_name
342,< nmbr,characteristic_name;characteristic_level,characteristic_level,< nmbr,characteristic_level
359,premenopausal,characteristic_name;characteristic_level,characteristic_name,premenopausal,characteristic_name
362,uncertain,characteristic_name;characteristic_level,characteristic_name,uncertain,characteristic_name
365,"postmenopausal , current hormone",characteristic_name;characteristic_level,characteristic_level,"postmenopausal , current hormone",characteristic_level
369,"postmenopausal ,",characteristic_name;characteristic_level,characteristic_name,"postmenopausal ,",characteristic_name
372,yes,characteristic_name;characteristic_level,characteristic_level,yes,characteristic_level
376,no,characteristic_name;characteristic_level,measures,no,measures
400,nmbr vitamin e,arms;measures,characteristic_level,nmbr vitamin e,characteristic_level
401,nmbr placebo,arms;measures,arms,nmbr placebo,arms
756,"postmenopausal , current hormone therapy use",characteristic_name;characteristic_level,characteristic_name,"postmenopausal , current hormone therapy use",characteristic_name
764,"postmenopausal , never or past hormone therapy use",characteristic_name;characteristic_level,characteristic_name,"postmenopausal , never or past hormone therapy use",characteristic_name
844,< nmbr . nmbr,characteristic_name;characteristic_level,characteristic_level,< nmbr . nmbr,characteristic_level
848,nmbr . nmbr - nmbr . nmbr,characteristic_name;characteristic_level,characteristic_level,nmbr . nmbr - nmbr . nmbr,characteristic_level
852,> nmbr . nmbr,characteristic_name;characteristic_level,characteristic_level,> nmbr . nmbr,characteristic_level
856,hr ( nmbr % ci ),measures;p-interaction,measures,hr ( nmbr % ci ),measures
857,p value for interaction,measures;p-interaction,measures,p value for interaction,measures
886,baseline mean ( mg / dl],measures;time/period,characteristic_level,baseline mean ( mg / dl],characteristic_level
894,( mmol / l],measures;time/period,outcomes,( mmol / l],outcomes
902,% change from baseline,measures;time/period,measures,% change from baseline,measures
910,( se] +,measures;time/period,outcomes,( se] +,outcomes
918,treatment difference,measures;time/period,other,treatment difference,other
926,"baseline mean , mg / dl",measures;time/period,characteristic_level,"baseline mean , mg / dl",characteristic_level
990,( se]t,measures;time/period,outcomes,( se]t,outcomes
1000,( se]tf,measures;time/period,outcomes,( se]tf,outcomes
1004,"baseline median , mg / dl",measures;time/period,outcomes,"baseline median , mg / dl",outcomes
1028,( nmbr % ell ' ll,measures;time/period,characteristic_level,( nmbr % ell ' ll,characteristic_level
1080,( se]t *,measures;time/period,outcomes,( se]t *,outcomes
1084,baseline mean,measures;time/period,characteristic_name,baseline mean,characteristic_name
1110,( se ) t *,measures;time/period,outcomes,( se ) t *,outcomes
1130,cse] +,measures;time/period,characteristic_name,cse] +,characteristic_name
1162,cg / ld,measures;time/period,characteristic_name,cg / ld,characteristic_name
1202,baseline median [mg / l],measures;time/period,arms,baseline median [mg / l],arms
1218,( nmbr % ci] nmbr,measures;time/period,measures,( nmbr % ci] nmbr,measures
1230,( nmbr % ci]h,measures;time/period,measures,( nmbr % ci]h,measures
1234,aged ^nmbr years,measures;characteristic_level,characteristic_level,aged ^nmbr years,characteristic_level
1237,aged < nmbr years,measures;characteristic_level,characteristic_level,aged < nmbr years,characteristic_level
1239,p value ( aged > nmbr vs . < nmbr years ),measures;characteristic_level,characteristic_level,p value ( aged > nmbr vs . < nmbr years ),characteristic_level
1457,atv n ( % ),arms;measures;p-interaction,characteristic_name,atv n ( % ),characteristic_name
1458,pbo n ( % ),arms;measures;p-interaction,characteristic_name,pbo n ( % ),characteristic_name
1459,rrr,arms;measures;p-interaction,characteristic_name,rrr,characteristic_name
1466,p - interaction,arms;measures;p-interaction,measures,p - interaction,measures
1497,total population,measures;characteristic_level,outcomes,total population,outcomes
1500,age ^nmbr,measures;characteristic_level,characteristic_name,age ^nmbr,characteristic_name
1503,age < nmbr,measures;characteristic_level,characteristic_name,age < nmbr,characteristic_name
1506,age - interaction,measures;characteristic_level,characteristic_name,age - interaction,characteristic_name
1510,aqe ^nmbr,measures;characteristic_level,characteristic_level,aqe ^nmbr,characteristic_level
1513,aqe < nmbr,measures;characteristic_level,characteristic_level,aqe < nmbr,characteristic_level
1520,aqe inmbr,measures;characteristic_level,arms,aqe inmbr,arms
1537,etoricoxib,arms;measures,arms,etoricoxib,arms
1539,diclofenac,arms;measures,arms,diclofenac,arms
1609,hazard ratio ( nmbr % ci ),arms;measures,measures,hazard ratio ( nmbr % ci ),measures
1726,all patients,characteristic_name;characteristic_level,characteristic_level,all patients,characteristic_level
1730,subgroups,characteristic_name;characteristic_level,characteristic_name,subgroups,characteristic_name
1734,patients with diabetesb,characteristic_name;characteristic_level,characteristic_level,patients with diabetesb,characteristic_level
1738,patients without diabetesb,characteristic_name;characteristic_level,characteristic_level,patients without diabetesb,characteristic_level
1742,patients with chronic,characteristic_name;characteristic_level,characteristic_level,patients with chronic,characteristic_level
1746,pulmonary disease,characteristic_name;characteristic_level,characteristic_name,pulmonary disease,characteristic_name
1750,patients without chronic,characteristic_name;characteristic_level,characteristic_level,patients without chronic,characteristic_level
1758,no . of patients,measures;p-interaction,characteristic_level,no . of patients,characteristic_level
1759,hazard ratio for event ( nmbr % ci ),measures;p-interaction,measures,hazard ratio for event ( nmbr % ci ),measures
1793,losartan,arms;measures,characteristic_name,losartan,characteristic_name
1796,placebo,arms;measures,arms,placebo,arms
1798,differencenmbr,arms;measures,characteristic_name,differencenmbr,characteristic_name
1799,p - valuec,arms;measures,measures,p - valuec,measures
1948,hr ( nmbr % cl ),arms;measures,measures,hr ( nmbr % cl ),measures
1949,p - value,arms;measures,measures,p - value,measures
1974,hazard ratio ( nmbr % ci ),measures;p-interaction,measures,hazard ratio ( nmbr % ci ),measures
1978,heterogeneity p value,measures;p-interaction,measures,heterogeneity p value,measures
1994,chd men,characteristic_level;outcomes,outcomes,chd men,outcomes
1996,women,characteristic_level;outcomes,characteristic_level,women,characteristic_level
1999,chd + cerebrovascular disease men nmbr / nmbr ( nmbr . nmbr ),characteristic_level;outcomes,characteristic_level,chd + cerebrovascular disease men nmbr / nmbr ( nmbr . nmbr ),characteristic_level
2004,men,characteristic_level;outcomes,characteristic_name,men,characteristic_name
2014,primary pci no .,arms;measures,outcomes,primary pci no .,outcomes
2015,combination - facilitated pci ( % ),arms;measures,characteristic_name,combination - facilitated pci ( % ),characteristic_name
2016,hazard ratio ( nmbr % confidence interval ),arms;measures,characteristic_name,hazard ratio ( nmbr % confidence interval ),characteristic_name
2110,region — no . ( % ),characteristic_name;outcomes,characteristic_name,region — no . ( % ),characteristic_name
2118,previous vascular disease,characteristic_name;outcomes,characteristic_name,previous vascular disease,characteristic_name
2134,"glycated hemoglobin , nonstandardized level — %",characteristic_name;outcomes,characteristic_name,"glycated hemoglobin , nonstandardized level — %",characteristic_name
2146,"glycated hemoglobin , standardized level — %",characteristic_name;outcomes,characteristic_name,"glycated hemoglobin , standardized level — %",characteristic_name
2158,fasting blood glucose — mmol / liter,characteristic_name;outcomes,characteristic_name,fasting blood glucose — mmol / liter,characteristic_name
2170,blood pressure — mm hg,characteristic_name;outcomes,characteristic_name,blood pressure — mm hg,characteristic_name
2178,serum cholesterol — mmol / liter,characteristic_name;outcomes,characteristic_name,serum cholesterol — mmol / liter,characteristic_name
2186,serum triglycerides — mmol / liter,characteristic_name;outcomes,outcomes,serum triglycerides — mmol / liter,outcomes
2218,glucose - lowering drug,characteristic_name;outcomes,characteristic_name,glucose - lowering drug,characteristic_name
2254,other drugs,characteristic_name;outcomes,characteristic_level,other drugs,characteristic_level
2274,"tg < nmbr , hdl > nmbr ( n = nmbr )",arms;measures,characteristic_level,"tg < nmbr , hdl > nmbr ( n = nmbr )",characteristic_level
2275,tg > nmbr . hdl < nmbr ( mg / dl ) ( / ? = nmbr ),arms;measures,characteristic_level,tg > nmbr . hdl < nmbr ( mg / dl ) ( / ? = nmbr ),characteristic_level
2276,p,arms;measures,characteristic_name,p,characteristic_name
2316,mean ( sd ),characteristic_level;measures,characteristic_level,mean ( sd ),characteristic_level
2318,"nmbr nmbr years , n ( % )",characteristic_level;measures,characteristic_level,"nmbr nmbr years , n ( % )",characteristic_level
2320,"> nmbr years , n ( % )",characteristic_level;measures,characteristic_level,"> nmbr years , n ( % )",characteristic_level
2322,"overall , male : female",characteristic_level;measures,characteristic_level,"overall , male : female",characteristic_level
2324,caucasian,characteristic_level;measures,characteristic_level,caucasian,characteristic_level
2326,black,characteristic_level;measures,characteristic_level,black,characteristic_level
2328,oriental,characteristic_level;measures,characteristic_name,oriental,characteristic_name
2330,other,characteristic_level;measures,characteristic_level,other,characteristic_level
2336,yes,characteristic_level;measures,characteristic_level,yes,characteristic_level
2338,no,characteristic_level;measures,measures,no,measures
2340,unknown,characteristic_level;measures,characteristic_level,unknown,characteristic_level
2342,mhis score,characteristic_level;measures,characteristic_level,mhis score,characteristic_level
2344,vadas score *,characteristic_level;measures,characteristic_level,vadas score *,characteristic_level
2346,adas - cog score *,characteristic_level;measures,characteristic_level,adas - cog score *,characteristic_level
2348,mmse score *,characteristic_level;measures,characteristic_level,mmse score *,characteristic_level
2350,adcs - adl score *,characteristic_level;measures,characteristic_level,adcs - adl score *,characteristic_level
2352,gds score *,characteristic_level;measures,characteristic_level,gds score *,characteristic_level
2354,npi - nmbr score *,characteristic_level;measures,characteristic_level,npi - nmbr score *,characteristic_level
2356,rates per nmbr patient - years,arms;measures,measures,rates per nmbr patient - years,measures
2415,subjects randomized,characteristic_level;measures,characteristic_level,subjects randomized,characteristic_level
2421,male,characteristic_level;measures,characteristic_level,male,characteristic_level
2424,female,characteristic_level;measures,arms,female,arms
2427,american indian / alaska native,characteristic_level;measures,characteristic_level,american indian / alaska native,characteristic_level
2430,asian,characteristic_level;measures,characteristic_level,asian,characteristic_level
2433,black or african - american,characteristic_level;measures,characteristic_level,black or african - american,characteristic_level
2436,white,characteristic_level;measures,characteristic_level,white,characteristic_level
2439,other *,characteristic_level;measures,characteristic_level,other *,characteristic_level
2442,hispanic or latino,characteristic_level;measures,characteristic_level,hispanic or latino,characteristic_level
2445,not hispanic or latino,characteristic_level;measures,characteristic_level,not hispanic or latino,characteristic_level
2451,completed trial,characteristic_level;measures,other,completed trial,other
2454,discontinued,characteristic_level;measures,characteristic_name,discontinued,characteristic_name
2457,adverse eventy,characteristic_level;measures,characteristic_name,adverse eventy,characteristic_name
2460,ineffective therapy,characteristic_level;measures,characteristic_name,ineffective therapy,characteristic_name
2463,non - compliance,characteristic_level;measures,characteristic_level,non - compliance,characteristic_level
2466,otherz,characteristic_level;measures,characteristic_name,otherz,characteristic_name
2481,abciximab ( n = nmbr ),arms;measures,characteristic_level,abciximab ( n = nmbr ),characteristic_level
2482,placebo ( n = nmbr ),arms;measures,arms,placebo ( n = nmbr ),arms
2539,p value for interaction,arms;measures,measures,p value for interaction,measures
2540,total no . of patients,arms;measures,characteristic_level,total no . of patients,characteristic_level
2541,clopidogrel plus aspirin % / yr,arms;measures,arms,clopidogrel plus aspirin % / yr,arms
2542,aspirin only,arms;measures,arms,aspirin only,arms
2651,p value for interaction,arms;measures;p-interaction,measures,p value for interaction,measures
2652,total no . of patients,arms;measures;p-interaction,characteristic_level,total no . of patients,characteristic_level
2653,clopidogrel plus aspirin % / yr,arms;measures;p-interaction,arms,clopidogrel plus aspirin % / yr,arms
2654,aspirin only,arms;measures;p-interaction,arms,aspirin only,arms
2763,"ischemia on cecg ( n = nmbr , nmbr )",measures;characteristic_level,characteristic_level,"ischemia on cecg ( n = nmbr , nmbr )",characteristic_level
2764,"no ischemia ( n = nmbr , nmbr )",measures;characteristic_level,characteristic_level,"no ischemia ( n = nmbr , nmbr )",characteristic_level
2765,p value,measures;characteristic_level,measures,p value,measures
2874,"ranolazine ( n = nmbr , nmbr )",arms;measures,arms,"ranolazine ( n = nmbr , nmbr )",arms
2875,"placebo ( n = nmbr , nmbr )",arms;measures,arms,"placebo ( n = nmbr , nmbr )",arms
2947,"weight , kg , median ( nmbrth , nmbrth )",characteristic_level;outcomes,characteristic_name,"weight , kg , median ( nmbrth , nmbrth )",characteristic_name
2950,diabetes mellitus,characteristic_level;outcomes,characteristic_name,diabetes mellitus,characteristic_name
2953,hypertension,characteristic_level;outcomes,characteristic_level,hypertension,characteristic_level
2956,hyperlipidemia,characteristic_level;outcomes,characteristic_level,hyperlipidemia,characteristic_level
2959,current smoker,characteristic_level;outcomes,characteristic_level,current smoker,characteristic_level
2962,prior mi,characteristic_level;outcomes,characteristic_level,prior mi,characteristic_level
2965,prior heart failure,characteristic_level;outcomes,characteristic_level,prior heart failure,characteristic_level
2968,prior coronary revascularization ( pci or cabg ),characteristic_level;outcomes,characteristic_level,prior coronary revascularization ( pci or cabg ),characteristic_level
2971,prior known stenosis > nmbr %,characteristic_level;outcomes,characteristic_level,prior known stenosis > nmbr %,characteristic_level
2974,nmbr - i,characteristic_level;outcomes,characteristic_level,nmbr - i,characteristic_level
2977,ii,characteristic_level;outcomes,characteristic_level,ii,characteristic_level
2979,iii - iv,characteristic_level;outcomes,characteristic_level,iii - iv,characteristic_level
2981,estimated creatinine clearance < nmbr ml / min *,characteristic_level;outcomes,characteristic_level,estimated creatinine clearance < nmbr ml / min *,characteristic_level
2984,coronary angiography during the index hospital stay,characteristic_level;outcomes,time/period,coronary angiography during the index hospital stay,time/period
2987,aspirin,characteristic_level;outcomes,arms,aspirin,arms
2990,thienopyridine,characteristic_level;outcomes,characteristic_level,thienopyridine,characteristic_level
2993,beta - blocker,characteristic_level;outcomes,characteristic_level,beta - blocker,characteristic_level
2996,calcium - channel blockerf,characteristic_level;outcomes,characteristic_name,calcium - channel blockerf,characteristic_name
2999,long acting nitratef,characteristic_level;outcomes,characteristic_level,long acting nitratef,characteristic_level
3002,ace inhibitor or angiotensin ii receptor blocker,characteristic_level;outcomes,characteristic_level,ace inhibitor or angiotensin ii receptor blocker,characteristic_level
3005,statin,characteristic_level;outcomes,characteristic_level,statin,characteristic_level
3008,"age , yrs , median ( nmbrth , nmbrth )",characteristic_level;outcomes,characteristic_name,"age , yrs , median ( nmbrth , nmbrth )",characteristic_name
3011,age ' ^nmbr yrs,characteristic_level;outcomes,characteristic_level,age ' ^nmbr yrs,characteristic_level
3014,female sex,characteristic_level;outcomes,characteristic_name,female sex,characteristic_name
3017,white race,characteristic_level;outcomes,characteristic_name,white race,characteristic_name
3020,diet,arms;measures;p-interaction,arms,diet,arms
3021,diet + pravastatin,arms;measures;p-interaction,arms,diet + pravastatin,arms
3022,hr ( nmbr % ci ),arms;measures;p-interaction,measures,hr ( nmbr % ci ),measures
3023,p - value,arms;measures;p-interaction,measures,p - value,measures
3080,lowest tg tertile,characteristic_name;characteristic_level,characteristic_level,lowest tg tertile,characteristic_level
3082,tgs ( mg / dl ),characteristic_name;characteristic_level,outcomes,tgs ( mg / dl ),outcomes
3086,ldl cholesterol ( mg / dl ),characteristic_name;characteristic_level,characteristic_level,ldl cholesterol ( mg / dl ),characteristic_level
3090,non - hdl cholesterol ( mg / dl ),characteristic_name;characteristic_level,characteristic_level,non - hdl cholesterol ( mg / dl ),characteristic_level
3094,apob ( mg / dl ),characteristic_name;characteristic_level,outcomes,apob ( mg / dl ),outcomes
3098,non - hdl cholesterol / apob ( ratio ),characteristic_name;characteristic_level,outcomes,non - hdl cholesterol / apob ( ratio ),outcomes
3102,middle tg tertile,characteristic_name;characteristic_level,characteristic_name,middle tg tertile,characteristic_name
3125,highest tg tertile,characteristic_name;characteristic_level,characteristic_level,highest tg tertile,characteristic_level
3148,n = nmbr,measures;time/period,characteristic_level,n = nmbr,characteristic_level
3149,n,measures;time/period,characteristic_name,n,characteristic_name
3150,baseline,measures;time/period,characteristic_name,baseline,characteristic_name
3151,treatment,measures;time/period,other,treatment,other
3216,"rasagiline , nmbr mg / day",arms;measures,arms,"rasagiline , nmbr mg / day",arms
3220,total ( n = nmbr ),arms;measures,characteristic_level,total ( n = nmbr ),characteristic_level
3251,hs - crp < nmbr . nmbr mg / l,measures;characteristic_level,arms,hs - crp < nmbr . nmbr mg / l,arms
3254,hs - crp > nmbr . nmbr mg / l,measures;characteristic_level,arms,hs - crp > nmbr . nmbr mg / l,arms
3257,"p , all vs all",measures;characteristic_level,characteristic_level,"p , all vs all",characteristic_level
3508,interaction p - valuenmbr,arms;measures;p-interaction,measures,interaction p - valuenmbr,measures
3543,"women ( n = nmbr ) , n / n ( % )",measures;p-interaction,characteristic_level,"women ( n = nmbr ) , n / n ( % )",characteristic_level
3544,"men ( n = nmbr ) , n / n ( % )",measures;p-interaction,characteristic_level,"men ( n = nmbr ) , n / n ( % )",characteristic_level
3545,p,measures;p-interaction,characteristic_name,p,characteristic_name
3593,p interaction women vs men,measures;p-interaction,measures,p interaction women vs men,measures
3607,ifx ( n = nmbr ),arms;measures,characteristic_level,ifx ( n = nmbr ),characteristic_level
3611,odds ratio,arms;measures,measures,odds ratio,measures
3612,nmbr % ci,arms;measures,measures,nmbr % ci,measures
3744,ifx + aza ( n = nmbr ),arms;measures,characteristic_level,ifx + aza ( n = nmbr ),characteristic_level
3840,macce ( % ),arms;measures;p-interaction,characteristic_name,macce ( % ),characteristic_name
3842,relative risk ( nmbr % confidence interval ),arms;measures;p-interaction,characteristic_level,relative risk ( nmbr % confidence interval ),characteristic_level
3907,clopidogrel ( n = nmbr ),arms;measures,arms,clopidogrel ( n = nmbr ),arms
3942,"all with coenzyme qnmbr ( n = nmbr , nmbr )",measures;characteristic_level,characteristic_level,"all with coenzyme qnmbr ( n = nmbr , nmbr )",characteristic_level
3943,tertile nmbr ( n = nmbr ),measures;characteristic_level,characteristic_level,tertile nmbr ( n = nmbr ),characteristic_level
3946,p value for trend across tertiles,measures;characteristic_level,measures,p value for trend across tertiles,measures
4125,interaction p value 中,arms;measures;p-interaction,measures,interaction p value 中,measures
4126,type of end point,arms;measures;p-interaction,outcomes,type of end point,outcomes
4127,placebo n ( rate ) *,arms;measures;p-interaction,arms,placebo n ( rate ) *,arms
4128,rosuvastatin n ( rate ),arms;measures;p-interaction,measures,rosuvastatin n ( rate ),measures
4129,hazard ratio,arms;measures;p-interaction,measures,hazard ratio,measures
4130,nmbr % ci,arms;measures;p-interaction,measures,nmbr % ci,measures
4131,subgroup p valuef,arms;measures;p-interaction,arms,subgroup p valuef,arms
4273,all - cause,characteristic_level;outcomes,outcomes,all - cause,outcomes
4274,tertile nmbr,characteristic_level;outcomes,characteristic_level,tertile nmbr,characteristic_level
4292,cardiovascular,characteristic_level;outcomes,characteristic_name,cardiovascular,characteristic_name
4311,worsening heart failure,characteristic_level;outcomes,outcomes,worsening heart failure,outcomes
4330,noncardiovascular,characteristic_level;outcomes,characteristic_name,noncardiovascular,characteristic_name
4349,median,characteristic_level;measures,characteristic_name,median,characteristic_name
4351,interquartile range,characteristic_level;measures,characteristic_level,interquartile range,characteristic_level
4353,male sex — no . / total no . ( % ),characteristic_level;measures,characteristic_level,male sex — no . / total no . ( % ),characteristic_level
4355,white race — no . / total no . ( % ) $,characteristic_level;measures,measures,white race — no . / total no . ( % ) $,measures
4361,negative for helicobacter pylori — no . / total no . ( % ),characteristic_level;measures,measures,negative for helicobacter pylori — no . / total no . ( % ),measures
4363,nsaid use — no . / total no . ( % ),characteristic_level;measures,characteristic_name,nsaid use — no . / total no . ( % ),characteristic_name
4365,pci,characteristic_level;measures,characteristic_name,pci,characteristic_name
4367,acs,characteristic_level;measures,characteristic_name,acs,characteristic_name
4369,mi,characteristic_level;measures,characteristic_level,mi,characteristic_level
4371,pad,characteristic_level;measures,characteristic_name,pad,characteristic_name
4373,stroke,characteristic_level;measures,characteristic_level,stroke,characteristic_level
4375,other vascular disease,characteristic_level;measures,characteristic_name,other vascular disease,characteristic_name
4377,hypertension,characteristic_level;measures,characteristic_level,hypertension,characteristic_level
4379,diabetes,characteristic_level;measures,characteristic_name,diabetes,characteristic_name
4381,hypercholesterolemia,characteristic_level;measures,characteristic_name,hypercholesterolemia,characteristic_name
4385,current smoking — no . / total no . ( % ),characteristic_level;measures,characteristic_level,current smoking — no . / total no . ( % ),characteristic_level
4387,current alcohol use — no . / total no . ( % ),characteristic_level;measures,characteristic_name,current alcohol use — no . / total no . ( % ),characteristic_name
4389,history of gi bleeding or ulcer — no . / total no . ( % ),characteristic_level;measures,measures,history of gi bleeding or ulcer — no . / total no . ( % ),measures
4391,aspirin,characteristic_level;measures,arms,aspirin,arms
4393,statin,characteristic_level;measures,characteristic_level,statin,characteristic_level
4395,clopidogrel,characteristic_level;measures,arms,clopidogrel,arms
4397,joint damage outcomes ( mitt population ),measures;outcomes,characteristic_name,joint damage outcomes ( mitt population ),characteristic_name
4404,change in mtss ( mean ),measures;outcomes,measures,change in mtss ( mean ),measures
4411,change in erosion score ( mean ),measures;outcomes,characteristic_level,change in erosion score ( mean ),characteristic_level
4418,% patients with no progression,measures;outcomes,characteristic_level,% patients with no progression,characteristic_level
4425,or ( unadjusted ),measures;outcomes,characteristic_name,or ( unadjusted ),characteristic_name
4429,nmbr % ci,measures;outcomes,measures,nmbr % ci,measures
4447,itt,measures;outcomes,time/period,itt,time/period
4454,acrnmbr,measures;outcomes,characteristic_name,acrnmbr,characteristic_name
4490,major clinical response,measures;outcomes,characteristic_name,major clinical response,characteristic_name
4497,mean acrn,measures;outcomes,characteristic_name,mean acrn,characteristic_name
4504,eular good response,measures;outcomes,characteristic_level,eular good response,characteristic_level
4511,dasnmbr - esr lda,measures;outcomes,characteristic_name,dasnmbr - esr lda,characteristic_name
4518,dasnmbr - esr remission,measures;outcomes,outcomes,dasnmbr - esr remission,outcomes
4525,change in dasnmbr - esr ( mean ) i physical function outcomes week nmbr,measures;outcomes,time/period,change in dasnmbr - esr ( mean ) i physical function outcomes week nmbr,time/period
4532,change in haq - di ( mean ) t,measures;outcomes,measures,change in haq - di ( mean ) t,measures
4539,% with haq - di decrease > nmbr . nmbr,measures;outcomes,characteristic_level,% with haq - di decrease > nmbr . nmbr,characteristic_level
4631,placebo patients with events,arms;p-interaction,measures,placebo patients with events,measures
4632,clopidogrel / total no . of patients % %,arms;p-interaction,characteristic_level,clopidogrel / total no . of patients % %,characteristic_level
4633,pvalue for heterogeneity,arms;p-interaction,characteristic_name,pvalue for heterogeneity,characteristic_name
4688,placebo patients with events / total,arms;p-interaction,measures,placebo patients with events / total,measures
4689,clopidogrel no . of patients % ),arms;p-interaction,characteristic_level,clopidogrel no . of patients % ),characteristic_level
4706,p value for heterogeneity,arms;p-interaction,measures,p value for heterogeneity,measures
4726,all patients with opg n - nmbr,measures;characteristic_level,characteristic_level,all patients with opg n - nmbr,characteristic_level
4727,tertile nmbr ( < nmbr . nmbr ng / ml ) n - nmbr,measures;characteristic_level,characteristic_level,tertile nmbr ( < nmbr . nmbr ng / ml ) n - nmbr,characteristic_level
4728,tertile nmbr ( nmbr . nmbr - nmbr . nmbr pg / ml ) n = nmbr,measures;characteristic_level,characteristic_level,tertile nmbr ( nmbr . nmbr - nmbr . nmbr pg / ml ) n = nmbr,characteristic_level
4729,tertile nmbr ( > nmbr . nmbr pg / ml ) n - nmbr,measures;characteristic_level,characteristic_level,tertile nmbr ( > nmbr . nmbr pg / ml ) n - nmbr,characteristic_level
4730,p trend,measures;characteristic_level,characteristic_name,p trend,characteristic_name
4960,rosuvastatin n ( rate ) *,arms;measures;p-interaction,measures,rosuvastatin n ( rate ) *,measures
4961,hazard ratiof,arms;measures;p-interaction,measures,hazard ratiof,measures
4962,nmbr % cit,arms;measures;p-interaction,characteristic_level,nmbr % cit,characteristic_level
4963,subgroup p value 本,arms;measures;p-interaction,arms,subgroup p value 本,arms
4979,interaction p value §,arms;measures;p-interaction,measures,interaction p value §,measures
5043,p value for heterogeneity,arms;measures,measures,p value for heterogeneity,measures
5044,pioglitazone,arms;measures,arms,pioglitazone,arms
5093,or nmbr % ci,measures;p-interaction,measures,or nmbr % ci,measures
5095,interaction p,measures;p-interaction,measures,interaction p,measures
5123,nadroparin,arms;measures,arms,nadroparin,arms
5124,control,arms;measures,arms,control,arms
5125,nadroparin vs control,arms;measures,arms,nadroparin vs control,arms
5135,persistent wrf ( n = nmbr ),arms;measures,characteristic_level,persistent wrf ( n = nmbr ),characteristic_level
5136,"no persistent wrf ( n = nmbr , nmbr )",arms;measures,characteristic_level,"no persistent wrf ( n = nmbr , nmbr )",characteristic_level
5137,difference ( nmbr % ci ) *,arms;measures,measures,difference ( nmbr % ci ) *,measures
5271,metabolic syndrome ( n = nmbr ),measures;characteristic_level,characteristic_name,metabolic syndrome ( n = nmbr ),characteristic_name
5272,nonmetabolic syndrome ( n = nmbr ),measures;characteristic_level,characteristic_level,nonmetabolic syndrome ( n = nmbr ),characteristic_level
5316,event / patients ( nmbr / pt - y ),arms;measures;p-interaction,characteristic_level,event / patients ( nmbr / pt - y ),characteristic_level
5320,nnt,arms;measures;p-interaction,characteristic_name,nnt,characteristic_name
5321,interaction - p,arms;measures;p-interaction,measures,interaction - p,measures
5374,overall,characteristic_name;characteristic_level,characteristic_name,overall,characteristic_name
5377,placebo allocation,characteristic_name;characteristic_level,arms,placebo allocation,arms
5380,omega nmbr allocation,characteristic_name;characteristic_level,characteristic_level,omega nmbr allocation,characteristic_level
5384,male,characteristic_name;characteristic_level,characteristic_level,male,characteristic_level
5387,female,characteristic_name;characteristic_level,arms,female,arms
5391,age < nmbr yrs,characteristic_name;characteristic_level,characteristic_level,age < nmbr yrs,characteristic_level
5394,age > = nmbr yrs,characteristic_name;characteristic_level,characteristic_level,age > = nmbr yrs,characteristic_level
5398,bmi < = nmbr,characteristic_name;characteristic_level,characteristic_level,bmi < = nmbr,characteristic_level
5401,bmi > nmbr,characteristic_name;characteristic_level,characteristic_level,bmi > nmbr,characteristic_level
5405,anmbrc < nmbr . nmbr % ( median ),characteristic_name;characteristic_level,characteristic_level,anmbrc < nmbr . nmbr % ( median ),characteristic_level
5408,anmbr = nmbr . nmbr % ( median ),characteristic_name;characteristic_level,characteristic_level,anmbr = nmbr . nmbr % ( median ),characteristic_level
5412,no prior cv event,characteristic_name;characteristic_level,characteristic_name,no prior cv event,characteristic_name
5415,prior cv event,characteristic_name;characteristic_level,characteristic_name,prior cv event,characteristic_name
5419,no metformin,characteristic_name;characteristic_level,characteristic_level,no metformin,characteristic_level
5422,metformin,characteristic_name;characteristic_level,characteristic_level,metformin,characteristic_level
5426,no statin use,characteristic_name;characteristic_level,characteristic_name,no statin use,characteristic_name
5429,statin use,characteristic_name;characteristic_level,characteristic_name,statin use,characteristic_name
5433,no ace - i / arb,characteristic_name;characteristic_level,characteristic_level,no ace - i / arb,characteristic_level
5436,ace - i / arb,characteristic_name;characteristic_level,characteristic_level,ace - i / arb,characteristic_level
5440,ifg / igt,characteristic_name;characteristic_level,characteristic_level,ifg / igt,characteristic_level
5443,new dm,characteristic_name;characteristic_level,characteristic_level,new dm,characteristic_level
5446,prior dm,characteristic_name;characteristic_level,characteristic_level,prior dm,characteristic_level
5450,hr ( nmbr % cl ),arms;measures;p-interaction,measures,hr ( nmbr % cl ),measures
5451,insulin glargine n ( % ) / nmbrpy,arms;measures;p-interaction,arms,insulin glargine n ( % ) / nmbrpy,arms
5452,standard care n ( % ) / nmbrpy,arms;measures;p-interaction,arms,standard care n ( % ) / nmbrpy,arms
5457,p,arms;measures;p-interaction,characteristic_name,p,characteristic_name
5534,endpoint,measures;time/period,time/period,endpoint,time/period
5542,a from baseline,measures;time/period,measures,a from baseline,measures
5550,p valuea,measures;time/period,characteristic_name,p valuea,characteristic_name
5822,baselinec,measures;time/period,characteristic_name,baselinec,characteristic_name
5830,endpointc,measures;time/period,characteristic_name,endpointc,characteristic_name
5838,endpoint / baseline,measures;time/period,characteristic_name,endpoint / baseline,characteristic_name
6087,endpoint / baselinec,measures;time/period,time/period,endpoint / baselinec,time/period
6099,decreased appetite,measures;outcomes;time/period,characteristic_name,decreased appetite,characteristic_name
6103,with an sfua,measures;outcomes;time/period,measures,with an sfua,measures
6107,without an sfua,measures;outcomes;time/period,characteristic_level,without an sfua,characteristic_level
6111,baselineb,measures;outcomes;time/period,characteristic_name,baselineb,characteristic_name
6115,a from baselineb,measures;outcomes;time/period,measures,a from baselineb,measures
6127,nausea,measures;outcomes;time/period,characteristic_name,nausea,characteristic_name
6131,vomiting,measures;outcomes;time/period,characteristic_name,vomiting,characteristic_name
6135,diarrhea,measures;outcomes;time/period,characteristic_name,diarrhea,characteristic_name
6139,nasopharyngitis,measures;outcomes;time/period,characteristic_name,nasopharyngitis,characteristic_name
6143,headache,measures;outcomes;time/period,characteristic_name,headache,characteristic_name
6147,upper respiratory tract infection,measures;outcomes;time/period,measures,upper respiratory tract infection,measures
6151,dizziness,measures;outcomes;time/period,characteristic_name,dizziness,characteristic_name
6155,dyspepsia,measures;outcomes;time/period,characteristic_name,dyspepsia,characteristic_name
6279,upper respiratory tract infection nmbr ( nmbr . nmbr ),measures;outcomes;time/period,characteristic_level,upper respiratory tract infection nmbr ( nmbr . nmbr ),characteristic_level
6308,control ( n = nmbr ),arms;measures,arms,control ( n = nmbr ),arms
6309,intensified ( n 二 nmbr ),arms;measures,characteristic_level,intensified ( n 二 nmbr ),characteristic_level
6347,control baseline ( n - nmbr ),arms;measures;time/period,arms,control baseline ( n - nmbr ),arms
6348,intensified baseline ( n - nmbr ),arms;measures;time/period,characteristic_level,intensified baseline ( n - nmbr ),characteristic_level
6349,p value,arms;measures;time/period,measures,p value,measures
6350,control nmbr months ( n - nmbr ),arms;measures;time/period,arms,control nmbr months ( n - nmbr ),arms
6351,intensified nmbr months ( n - nmbr ),arms;measures;time/period,characteristic_level,intensified nmbr months ( n - nmbr ),characteristic_level
6438,ipst ( n = nmbr ),arms;measures,characteristic_level,ipst ( n = nmbr ),characteristic_level
6439,"no ipst ( n = nmbr , nmbr )",arms;measures,characteristic_level,"no ipst ( n = nmbr , nmbr )",characteristic_level
6527,p — value for interaction,arms;measures;p-interaction,measures,p — value for interaction,measures
6528,n nmbr,arms;measures;p-interaction,characteristic_level,n nmbr,characteristic_level
6530,[nmbr % cl],arms;measures;p-interaction,measures,[nmbr % cl],measures
6531,losartan + placebo,arms;measures;p-interaction,arms,losartan + placebo,arms
6532,losartan + lisinopril,arms;measures;p-interaction,characteristic_name,losartan + lisinopril,characteristic_name
6587,p value for interaction,arms;p-interaction,measures,p value for interaction,measures
6588,stent plus medical therapy,arms;p-interaction,arms,stent plus medical therapy,arms
6589,medical therapy alone,arms;p-interaction,characteristic_name,medical therapy alone,characteristic_name
6590,hazard ratio ( nmbr % cl ),arms;p-interaction,measures,hazard ratio ( nmbr % cl ),measures
6660,"baseline fev , ( l )",characteristic_name;characteristic_level,characteristic_name,"baseline fev , ( l )",characteristic_name
6663,age ( yr ),characteristic_name;characteristic_level,characteristic_name,age ( yr ),characteristic_name
6667,sex,characteristic_name;characteristic_level,characteristic_name,sex,characteristic_name
6668,m,characteristic_name;characteristic_level,characteristic_name,m,characteristic_name
6669,f,characteristic_name;characteristic_level,characteristic_name,f,characteristic_name
6670,grouped region,characteristic_name;characteristic_level,characteristic_name,grouped region,characteristic_name
6671,australasia,characteristic_name;characteristic_level,characteristic_name,australasia,characteristic_name
6672,europe,characteristic_name;characteristic_level,characteristic_level,europe,characteristic_level
6673,latin america,characteristic_name;characteristic_level,characteristic_level,latin america,characteristic_level
6674,united states,characteristic_name;characteristic_level,characteristic_level,united states,characteristic_level
6675,total ( n = nmbr ),measures;other,characteristic_level,total ( n = nmbr ),characteristic_level
6676,no readmission ( n = nmbr ),measures;other,characteristic_level,no readmission ( n = nmbr ),characteristic_level
6677,readmission ( n = nmbr ),measures;other,characteristic_level,readmission ( n = nmbr ),characteristic_level
6678,p value,measures;other,measures,p value,measures
6755,no . of events / patients,measures;p-interaction,measures,no . of events / patients,measures
6866,"age - years , median ( iqr )",characteristic_name;characteristic_level,characteristic_name,"age - years , median ( iqr )",characteristic_name
6869,"age > nmbr years , n ( % )",characteristic_name;characteristic_level,characteristic_name,"age > nmbr years , n ( % )",characteristic_name
6872,"male , n ( % )",characteristic_name;characteristic_level,characteristic_level,"male , n ( % )",characteristic_level
6875,race,characteristic_name;characteristic_level,characteristic_name,race,characteristic_name
6876,"white , n ( % )",characteristic_name;characteristic_level,characteristic_level,"white , n ( % )",characteristic_level
6878,"black , n ( % )",characteristic_name;characteristic_level,characteristic_level,"black , n ( % )",characteristic_level
6880,"asian , n ( % )",characteristic_name;characteristic_level,characteristic_level,"asian , n ( % )",characteristic_level
6882,"multiracial , n ( % )",characteristic_name;characteristic_level,characteristic_name,"multiracial , n ( % )",characteristic_name
6884,"other , n ( % )",characteristic_name;characteristic_level,characteristic_level,"other , n ( % )",characteristic_level
6886,"hispanic , n ( % )",characteristic_name;characteristic_level,characteristic_level,"hispanic , n ( % )",characteristic_level
6889,"weight - kg , median ( iqr )",characteristic_name;characteristic_level,outcomes,"weight - kg , median ( iqr )",outcomes
6892,"weight > nmbr kg , n ( % )",characteristic_name;characteristic_level,characteristic_level,"weight > nmbr kg , n ( % )",characteristic_level
6895,"body - mass index - kg / mnmbr , median ( iqr )",characteristic_name;characteristic_level,characteristic_name,"body - mass index - kg / mnmbr , median ( iqr )",characteristic_name
6898,"body - mass index > nmbr , n ( % )",characteristic_name;characteristic_level,characteristic_name,"body - mass index > nmbr , n ( % )",characteristic_name
6901,"duration of diabetes , median ( iqr )",characteristic_name;characteristic_level,characteristic_name,"duration of diabetes , median ( iqr )",characteristic_name
6904,"established atherosclerotic disease , n ( % )",characteristic_name;characteristic_level,characteristic_name,"established atherosclerotic disease , n ( % )",characteristic_name
6907,"hypertension , n ( % )",characteristic_name;characteristic_level,characteristic_level,"hypertension , n ( % )",characteristic_level
6910,"dyslipidemia , n ( % )",characteristic_name;characteristic_level,characteristic_level,"dyslipidemia , n ( % )",characteristic_level
6913,"prior myocardial infarction , n ( % )",characteristic_name;characteristic_level,characteristic_name,"prior myocardial infarction , n ( % )",characteristic_name
6916,"prior coronary revascularization , n ( % )",characteristic_name;characteristic_level,characteristic_level,"prior coronary revascularization , n ( % )",characteristic_level
6919,"glycated hemoglobin , median ( iqr )",characteristic_name;characteristic_level,characteristic_name,"glycated hemoglobin , median ( iqr )",characteristic_name
6922,"glycated hemoglobin , n ( % )",characteristic_name;characteristic_level,characteristic_name,"glycated hemoglobin , n ( % )",characteristic_name
6923,< nmbr . nmbr %,characteristic_name;characteristic_level,characteristic_level,< nmbr . nmbr %,characteristic_level
6925,nmbr . nmbr - < nmbr . nmbr %,characteristic_name;characteristic_level,characteristic_level,nmbr . nmbr - < nmbr . nmbr %,characteristic_level
6931,> nmbr . nmbr %,characteristic_name;characteristic_level,characteristic_level,> nmbr . nmbr %,characteristic_level
6933,"fasting serum glucose ( mg / dl ) , median ( iqr )",characteristic_name;characteristic_level,characteristic_level,"fasting serum glucose ( mg / dl ) , median ( iqr )",characteristic_level
6936,"estimated glomerular filtration rate - ml / min , median ( iqr ) '",characteristic_name;characteristic_level,characteristic_name,"estimated glomerular filtration rate - ml / min , median ( iqr ) '",characteristic_name
6939,"estimated glomerular filtration rate , n ( % )",characteristic_name;characteristic_level,measures,"estimated glomerular filtration rate , n ( % )",measures
6940,< nmbr ml / min,characteristic_name;characteristic_level,characteristic_level,< nmbr ml / min,characteristic_level
6942,nmbr - < nmbr ml / min,characteristic_name;characteristic_level,characteristic_level,nmbr - < nmbr ml / min,characteristic_level
6944,> nmbr ml / min,characteristic_name;characteristic_level,characteristic_level,> nmbr ml / min,characteristic_level
6946,"albumin / creatinine ratio - mg / mmol , median ( iqr )",characteristic_name;characteristic_level,arms,"albumin / creatinine ratio - mg / mmol , median ( iqr )",arms
6949,"albumin / creatinine ratio , n ( % )",characteristic_name;characteristic_level,characteristic_name,"albumin / creatinine ratio , n ( % )",characteristic_name
6950,< nmbr . nmbr mg / mmol,characteristic_name;characteristic_level,arms,< nmbr . nmbr mg / mmol,arms
6952,nmbr . nmbr - < nmbr . nmbr mg / mmol,characteristic_name;characteristic_level,characteristic_level,nmbr . nmbr - < nmbr . nmbr mg / mmol,characteristic_level
6954,> nmbr . nmbr mg / mmol,characteristic_name;characteristic_level,arms,> nmbr . nmbr mg / mmol,arms
6956,aspirin,characteristic_name;characteristic_level,arms,aspirin,arms
6959,beta - blockers,characteristic_name;characteristic_level,characteristic_name,beta - blockers,characteristic_name
6962,ace inhibitors,characteristic_name;characteristic_level,characteristic_name,ace inhibitors,characteristic_name
6965,angiotensin receptor blockers,characteristic_name;characteristic_level,characteristic_level,angiotensin receptor blockers,characteristic_level
6968,diuretics,characteristic_name;characteristic_level,characteristic_name,diuretics,characteristic_name
6971,statins,characteristic_name;characteristic_level,outcomes,statins,outcomes
6974,calcium antagonists,characteristic_name;characteristic_level,characteristic_name,calcium antagonists,characteristic_name
6980,sulfonylurea,characteristic_name;characteristic_level,characteristic_name,sulfonylurea,characteristic_name
6983,thiazolidinediones,characteristic_name;characteristic_level,characteristic_level,thiazolidinediones,characteristic_level
6986,insulin,characteristic_name;characteristic_level,characteristic_level,insulin,characteristic_level
6989,"prior heart failure ( n = nmbr , nmbr )",characteristic_name;p-interaction,characteristic_level,"prior heart failure ( n = nmbr , nmbr )",characteristic_level
6990,"no prior heart failure ( n = nmbr , nmbr )",characteristic_name;p-interaction,characteristic_level,"no prior heart failure ( n = nmbr , nmbr )",characteristic_level
6991,p - value,characteristic_name;p-interaction,measures,p - value,measures
7112,n,arms;measures;p-interaction,characteristic_name,n,characteristic_name
7113,saxagliptin,arms;measures;p-interaction,arms,saxagliptin,arms
7114,placebo,arms;measures;p-interaction,arms,placebo,arms
7116,p for interaction,arms;measures;p-interaction,measures,p for interaction,measures
7324,fp / sal nmbr / nmbr pg ( n = nmbr ),arms;measures;p-interaction,characteristic_level,fp / sal nmbr / nmbr pg ( n = nmbr ),characteristic_level
7325,sal nmbr pg ( n = nmbr ),arms;measures;p-interaction,characteristic_level,sal nmbr pg ( n = nmbr ),characteristic_level
7330,ratio fp / sal : sal ( nmbr % ci ),arms;measures;p-interaction,measures,ratio fp / sal : sal ( nmbr % ci ),measures
7331,p value,arms;measures;p-interaction,measures,p value,measures
7393,americas ( n = nmbr ),arms;measures,characteristic_level,americas ( n = nmbr ),characteristic_level
7394,russia / georgia ( n = nmbr ),arms;measures,characteristic_level,russia / georgia ( n = nmbr ),characteristic_level
7517,spironolactone ( n = nmbr ),arms;measures,characteristic_name,spironolactone ( n = nmbr ),characteristic_name
7519,hr ( nmbr % ci ) p   value,arms;measures,measures,hr ( nmbr % ci ) p   value,measures
7621,americas ( n = nmbr ),measures;characteristic_level,characteristic_level,americas ( n = nmbr ),characteristic_level
7624,russia / georgia ( n = nmbr ),measures;characteristic_level,characteristic_level,russia / georgia ( n = nmbr ),characteristic_level
7627,"p , regional difference *",measures;characteristic_level,outcomes,"p , regional difference *",outcomes
7628,"p , treatment - by - region interaction",measures;characteristic_level,characteristic_name,"p , treatment - by - region interaction",characteristic_name
7725,total no .,arms;measures;p-interaction,measures,total no .,measures
7726,vorapaxar nmbr - y,arms;measures;p-interaction,characteristic_level,vorapaxar nmbr - y,characteristic_level
7727,placebo r %,arms;measures;p-interaction,arms,placebo r %,arms
7729,p - value for interaction,arms;measures;p-interaction,measures,p - value for interaction,measures
7797,vorapaxar ( n = nmbr . nmbr ),arms;measures,characteristic_level,vorapaxar ( n = nmbr . nmbr ),characteristic_level
7798,placebo ( n - nmbr . nmbr ),arms;measures,arms,placebo ( n - nmbr . nmbr ),arms
7854,"egfr . nmbr ml / min / nmbr . nmbr mnmbr ( n = nmbr , nmbr )",measures;characteristic_level,characteristic_level,"egfr . nmbr ml / min / nmbr . nmbr mnmbr ( n = nmbr , nmbr )",characteristic_level
7855,"egfr nmbr - nmbr ml / min / nmbr . nmbr mnmbr ( n = nmbr , nmbr )",measures;characteristic_level,characteristic_level,"egfr nmbr - nmbr ml / min / nmbr . nmbr mnmbr ( n = nmbr , nmbr )",characteristic_level
7856,"egfr , nmbr ml / min / nmbr . nmbr mnmbr ( n = nmbr )",measures;characteristic_level,characteristic_level,"egfr , nmbr ml / min / nmbr . nmbr mnmbr ( n = nmbr )",characteristic_level
7857,p,measures;characteristic_level,characteristic_name,p,characteristic_name
7989,olmesartan ( n = nmbr ),arms;measures,characteristic_level,olmesartan ( n = nmbr ),characteristic_level
8086,number,measures;p-interaction,characteristic_name,number,characteristic_name
8087,hazard,measures;p-interaction,characteristic_name,hazard,characteristic_name
8088,nmbr % c . i .,measures;p-interaction,characteristic_level,nmbr % c . i .,characteristic_level
8091,p - value for interaction,measures;p-interaction,measures,p - value for interaction,measures
8218,taci ( n = nmbr ),measures;characteristic_level,characteristic_level,taci ( n = nmbr ),characteristic_level
8219,paci ( n = nmbr ),measures;characteristic_level,characteristic_level,paci ( n = nmbr ),characteristic_level
8220,poci ( n = nmbr ),measures;characteristic_level,characteristic_level,poci ( n = nmbr ),characteristic_level
8221,laci ( n = nmbr ),measures;characteristic_level,characteristic_level,laci ( n = nmbr ),characteristic_level
8282,candesartan nmbr / nmbr,arms;measures,characteristic_level,candesartan nmbr / nmbr,characteristic_level
8283,placebo nmbr / nmbr,arms;measures,arms,placebo nmbr / nmbr,arms
8289,hbanmbrc at nmbr weeks *,outcomes;time/period,characteristic_level,hbanmbrc at nmbr weeks *,characteristic_level
8295,"baseline , mean ( sd )",outcomes;time/period,characteristic_level,"baseline , mean ( sd )",characteristic_level
8307,"change from baseline , adjusted mean ( nmbr % ci )",outcomes;time/period,measures,"change from baseline , adjusted mean ( nmbr % ci )",measures
8319,responders of three - item end point at nmbr weeks *,outcomes;time/period,outcomes,responders of three - item end point at nmbr weeks *,outcomes
8331,"seated sbp at nmbr weeks , mmhg + * *",outcomes;time/period,characteristic_level,"seated sbp at nmbr weeks , mmhg + * *",characteristic_level
8349,"bw at nmbr weeks , kg +",outcomes;time/period,characteristic_level,"bw at nmbr weeks , kg +",characteristic_level
8367,"seated sbp at nmbr weeks , mmhg +",outcomes;time/period,characteristic_level,"seated sbp at nmbr weeks , mmhg +",characteristic_level
8385,patients with bw decrease of $ nmbr % in patients with baseline bmi of $ nmbr kg / mnmbr +,outcomes;time/period,characteristic_level,patients with bw decrease of $ nmbr % in patients with baseline bmi of $ nmbr kg / mnmbr +,characteristic_level
8397,"fpg , mmol / lt",outcomes;time/period,outcomes,"fpg , mmol / lt",outcomes
8415,"aspirin only ( n = nmbr , nmbr )",arms;measures,characteristic_level,"aspirin only ( n = nmbr , nmbr )",characteristic_level
8416,"aspirin i clopidogrel ( n = nmbr , nmbr )",arms;measures,arms,"aspirin i clopidogrel ( n = nmbr , nmbr )",arms
8498,era and pdenmbr inhibitors,characteristic_name;characteristic_level,characteristic_name,era and pdenmbr inhibitors,characteristic_name
8500,era monotherapy,characteristic_name;characteristic_level,characteristic_name,era monotherapy,characteristic_name
8502,pdenmbr inhibitor monotherapy,characteristic_name;characteristic_level,characteristic_level,pdenmbr inhibitor monotherapy,characteristic_level
8504,no pah therapy,characteristic_name;characteristic_level,characteristic_level,no pah therapy,characteristic_level
8506,l / ll,characteristic_name;characteristic_level,characteristic_name,l / ll,characteristic_name
8508,iii / iv,characteristic_name;characteristic_level,characteristic_level,iii / iv,characteristic_level
8516,nmbr years,characteristic_name;characteristic_level,characteristic_level,nmbr years,characteristic_level
8518,"ipah , hpah , hiv , drug or toxin induced",characteristic_name;characteristic_level,characteristic_name,"ipah , hpah , hiv , drug or toxin induced",characteristic_name
8520,"assoc , with connective tissue disease",characteristic_name;characteristic_level,measures,"assoc , with connective tissue disease",measures
8522,"assoc , with corrected congenital shunts",characteristic_name;characteristic_level,measures,"assoc , with corrected congenital shunts",measures
8524,north america,characteristic_name;characteristic_level,characteristic_name,north america,characteristic_name
8526,western europe / australia,characteristic_name;characteristic_level,characteristic_level,western europe / australia,characteristic_level
8528,eastern europe,characteristic_name;characteristic_level,characteristic_level,eastern europe,characteristic_level
8530,asia,characteristic_name;characteristic_level,characteristic_level,asia,characteristic_level
8534,placebo,arms;p-interaction,arms,placebo,arms
8535,selexipag,arms;p-interaction,characteristic_name,selexipag,characteristic_name
8572,bivalirudin ( n = nmbr ),arms;p-interaction,characteristic_level,bivalirudin ( n = nmbr ),characteristic_level
8573,control ( n = nmbr ),arms;p-interaction,arms,control ( n = nmbr ),arms
8620,cangrelor ( n = nmbr ) n / n ( % ),arms;measures,arms,cangrelor ( n = nmbr ) n / n ( % ),arms
8621,clopidogrel ( n = nmbr ) n / n ( % ),arms;measures,arms,clopidogrel ( n = nmbr ) n / n ( % ),arms
8622,unadjusted or ( nmbr % ci ) p value,arms;measures,measures,unadjusted or ( nmbr % ci ) p value,measures
8623,adjusted * or ( nmbr % ci ) p value,arms;measures,measures,adjusted * or ( nmbr % ci ) p value,measures
8719,women,characteristic_level;p-interaction,characteristic_level,women,characteristic_level
8723,men,characteristic_level;p-interaction,characteristic_name,men,characteristic_name
8727,p interaction ( rx arm * sex ),characteristic_level;p-interaction,measures,p interaction ( rx arm * sex ),measures
8818,aliskiren,arms;measures;p-interaction,arms,aliskiren,arms
8828,pinteraction,arms;measures;p-interaction,characteristic_name,pinteraction,characteristic_name
8872,renal subgroup,characteristic_level;outcomes,arms,renal subgroup,arms
8877,normoalbuminuria or microalbuminuria,characteristic_level;outcomes,characteristic_name,normoalbuminuria or microalbuminuria,characteristic_name
8883,macroalbuminuria,characteristic_level;outcomes,characteristic_name,macroalbuminuria,characteristic_name
8888,egfr > nmbr ml / min / nmbr - nmbr mnmbr,characteristic_level;outcomes,characteristic_level,egfr > nmbr ml / min / nmbr - nmbr mnmbr,characteristic_level
8894,egfr < nmbr ml / min / nmbr - nmbr mnmbr,characteristic_level;outcomes,characteristic_level,egfr < nmbr ml / min / nmbr - nmbr mnmbr,characteristic_level
8920,cardiovascu lar subg roup,characteristic_level;outcomes,characteristic_name,cardiovascu lar subg roup,characteristic_name
8926,number of e,measures;p-interaction,characteristic_name,number of e,characteristic_name
8927,vents / patients,measures;p-interaction,characteristic_level,vents / patients,characteristic_level
8928,hazard ratio,measures;p-interaction,measures,hazard ratio,measures
8929,pfor heterogeneity,measures;p-interaction,characteristic_name,pfor heterogeneity,characteristic_name
9013,continued thienopyridine ( n = nmbr ),arms;measures,characteristic_level,continued thienopyridine ( n = nmbr ),characteristic_level
9149,patients with diabetes mellitus,measures;characteristic_level,characteristic_level,patients with diabetes mellitus,characteristic_level
9291,baseline mean ( se ),measures;time/period,outcomes,baseline mean ( se ),outcomes
9297,week nmbr mean ( se ),measures;time/period,time/period,week nmbr mean ( se ),time/period
9303,adjusted mean change,measures;time/period,measures,adjusted mean change,measures
9309,from baseline ( nmbr % ci ),measures;time/period,measures,from baseline ( nmbr % ci ),measures
9315,difference from placebo,measures;time/period,arms,difference from placebo,arms
9321,( nmbr % ci ),measures;time/period,measures,( nmbr % ci ),measures
9403,age,characteristic_name;characteristic_level,characteristic_name,age,characteristic_name
9407,previous statin use,characteristic_name;characteristic_level,characteristic_name,previous statin use,characteristic_name
9409,troponin nmbr at baseline,characteristic_name;characteristic_level,characteristic_level,troponin nmbr at baseline,characteristic_level
9411,duration of assigned regimen before surgery,characteristic_name;characteristic_level,characteristic_name,duration of assigned regimen before surgery,characteristic_name
9413,surgical technique,characteristic_name;characteristic_level,characteristic_name,surgical technique,characteristic_name
9415,procedure,characteristic_name;characteristic_level,characteristic_name,procedure,characteristic_name
9417,postoperative glucocorticoid use,characteristic_name;characteristic_level,characteristic_name,postoperative glucocorticoid use,characteristic_name
9419,postoperative nsaid or glucocorticoid use,characteristic_name;characteristic_level,characteristic_name,postoperative nsaid or glucocorticoid use,characteristic_name
9423,clopidogrel plus aspirin ( n = nmbr ),arms;measures,arms,clopidogrel plus aspirin ( n = nmbr ),arms
9424,aspirin ( n = nmbr ),arms;measures,characteristic_level,aspirin ( n = nmbr ),characteristic_level
9490,< nmbr,measures;characteristic_level,characteristic_level,< nmbr,characteristic_level
9491,nnmbr,measures;characteristic_level,characteristic_level,nnmbr,characteristic_level
9492,p - value,measures;characteristic_level,measures,p - value,measures
9599,on omt,measures;characteristic_level,characteristic_name,on omt,characteristic_name
9601,off omt,measures;characteristic_level,characteristic_name,off omt,characteristic_name
9603,on omt ( n = nmbr ),measures;characteristic_level,characteristic_level,on omt ( n = nmbr ),characteristic_level
9604,off omt ( n = nmbr ),measures;characteristic_level,characteristic_level,off omt ( n = nmbr ),characteristic_level
9617,p value ( on vs off omt ),measures;characteristic_level,measures,p value ( on vs off omt ),measures
9868,baricitinib nmbr mg,arms;p-interaction,arms,baricitinib nmbr mg,arms
9873,simva,arms;measures,arms,simva,arms
9874,ez / simva,arms;measures,arms,ez / simva,arms
9875,hr,arms;measures,measures,hr,measures
9876,arr,arms;measures,characteristic_name,arr,characteristic_name
9885,p - int,arms;measures,characteristic_name,p - int,characteristic_name
10198,overall population,measures;characteristic_level,characteristic_name,overall population,characteristic_name
10202,minimal important change threshold ( improvement ) a,measures;characteristic_level,outcomes,minimal important change threshold ( improvement ) a,outcomes
10203,> nmbr % focal seizure frequency responders,measures;characteristic_level,characteristic_level,> nmbr % focal seizure frequency responders,characteristic_level
10270,"female , n ( % )",characteristic_level;measures,arms,"female , n ( % )",arms
10278,nmbr - nmbr,characteristic_level;measures,characteristic_level,nmbr - nmbr,characteristic_level
10294,> nmbr,characteristic_level;measures,characteristic_level,> nmbr,characteristic_level
10302,"baseline focal seizure frequency / nmbr days , median ( qnmbr , qnmbr )",characteristic_level;measures,characteristic_level,"baseline focal seizure frequency / nmbr days , median ( qnmbr , qnmbr )",characteristic_level
10310,"age , mean ( sd ) , years",characteristic_level;measures,characteristic_name,"age , mean ( sd ) , years",characteristic_name
10318,p - value for interaction,arms;measures,measures,p - value for interaction,measures
10321,empagliflozin,arms;measures,characteristic_name,empagliflozin,characteristic_name
10323,hr ( nmbr % ci ),arms;measures,measures,hr ( nmbr % ci ),measures
10789,age,characteristic_name;p-interaction,characteristic_name,age,characteristic_name
10802,sex,characteristic_name;p-interaction,characteristic_name,sex,characteristic_name
10815,race,characteristic_name;p-interaction,characteristic_name,race,characteristic_name
10840,ethnicity,characteristic_name;p-interaction,characteristic_name,ethnicity,characteristic_name
10853,region,characteristic_name;p-interaction,characteristic_name,region,characteristic_name
10883,time since diagnosis of type nmbr diabetes,characteristic_name;p-interaction,characteristic_level,time since diagnosis of type nmbr diabetes,characteristic_level
10902,hbanmbrc,characteristic_name;p-interaction,outcomes,hbanmbrc,outcomes
10915,body mass index,characteristic_name;p-interaction,characteristic_name,body mass index,characteristic_name
10928,egfr,characteristic_name;p-interaction,characteristic_name,egfr,characteristic_name
10947,urine albumin - to - creatinine ratio,characteristic_name;p-interaction,characteristic_name,urine albumin - to - creatinine ratio,characteristic_name
10966,blood pressure control,characteristic_name;p-interaction,arms,blood pressure control,arms
10977,cardiovascular risk,characteristic_name;p-interaction,characteristic_name,cardiovascular risk,characteristic_name
11001,previous stroke,characteristic_name;p-interaction,characteristic_level,previous stroke,characteristic_level
11014,atrial fibrillation,characteristic_name;p-interaction,characteristic_name,atrial fibrillation,characteristic_name
11027,heart failure,characteristic_name;p-interaction,characteristic_name,heart failure,characteristic_name
11053,smoking status,characteristic_name;p-interaction,characteristic_name,smoking status,characteristic_name
11072,metformin,characteristic_name;p-interaction,characteristic_level,metformin,characteristic_level
11085,sulfonylurea,characteristic_name;p-interaction,characteristic_name,sulfonylurea,characteristic_name
11098,insulin,characteristic_name;p-interaction,characteristic_level,insulin,characteristic_level
11124,dpp - nmbr inhibitor,characteristic_name;p-interaction,characteristic_level,dpp - nmbr inhibitor,characteristic_level
11137,statin or ezetimibe,characteristic_name;p-interaction,characteristic_level,statin or ezetimibe,characteristic_level
11163,ace inhibitor or arb,characteristic_name;p-interaction,characteristic_level,ace inhibitor or arb,characteristic_level
11176,calcium channel blocker,characteristic_name;p-interaction,characteristic_level,calcium channel blocker,characteristic_level
11189,beta - blocker,characteristic_name;p-interaction,characteristic_level,beta - blocker,characteristic_level
11202,diuretic,characteristic_name;p-interaction,characteristic_level,diuretic,characteristic_level
11215,loop diuretic,characteristic_name;p-interaction,characteristic_level,loop diuretic,characteristic_level
11228,acetylsalicylic acid,characteristic_name;p-interaction,characteristic_name,acetylsalicylic acid,characteristic_name
11241,vitamin k antagonist,characteristic_name;p-interaction,characteristic_name,vitamin k antagonist,characteristic_name
11254,baseline ( n ),measures;time/period,characteristic_name,baseline ( n ),characteristic_name
11262,week nmbr,measures;time/period,time/period,week nmbr,time/period
11266,mean change at week nmbr,measures;time/period,time/period,mean change at week nmbr,time/period
11270,mean difference = seb,measures;time/period,outcomes,mean difference = seb,outcomes
11272,p - value,measures;time/period,measures,p - value,measures
11302,mean = sd,measures;time/period,characteristic_level,mean = sd,characteristic_level
11309,tofacitinib nmbr mg bid,arms;measures,arms,tofacitinib nmbr mg bid,arms
11318,difference,arms;measures,outcomes,difference,outcomes
11458,without psoriasis ( zi = nmbr ),characteristic_level;p-interaction,characteristic_level,without psoriasis ( zi = nmbr ),characteristic_level
11459,with psoriasis ( zi = nmbr ),characteristic_level;p-interaction,characteristic_level,with psoriasis ( zi = nmbr ),characteristic_level
11460,p valuenmbr,characteristic_level;p-interaction,arms,p valuenmbr,arms
11461,"without psoriasis ( zi = nmbr , nmbr )",characteristic_level;p-interaction,characteristic_level,"without psoriasis ( zi = nmbr , nmbr )",characteristic_level
11463,p value * nmbr,characteristic_level;p-interaction,measures,p value * nmbr,measures
11636,atorvastatin ls means difference nmbr mg ( nmbr % ci ) a ( n = nmbr ),arms;measures,arms,atorvastatin ls means difference nmbr mg ( nmbr % ci ) a ( n = nmbr ),arms
11637,p valuenmbr,arms;measures,arms,p valuenmbr,arms
11639,atorvastatin nmbr mg ( n = nmbr ),arms;measures,arms,atorvastatin nmbr mg ( n = nmbr ),arms
11640,ls means difference ( nmbr % ci ) nmbr,arms;measures,measures,ls means difference ( nmbr % ci ) nmbr,measures
11707,patients without psoriasis ( n = nmbr ),characteristic_level;p-interaction,characteristic_level,patients without psoriasis ( n = nmbr ),characteristic_level
11710,patients with psoriasis ( n = nmbr ),characteristic_level;p-interaction,characteristic_level,patients with psoriasis ( n = nmbr ),characteristic_level
11714,interaction : treatment by psoriasis p valuenmbr,characteristic_level;p-interaction,characteristic_name,interaction : treatment by psoriasis p valuenmbr,characteristic_name
11779,canagliflozin ( n = nmbr ),arms;measures,characteristic_level,canagliflozin ( n = nmbr ),characteristic_level
11781,"total ( n = nmbr , nmbr ) - -",arms;measures,characteristic_level,"total ( n = nmbr , nmbr ) - -",characteristic_level
11878,< nmbr y ( n = nmbr ),measures;characteristic_level,characteristic_level,< nmbr y ( n = nmbr ),characteristic_level
11879,> nmbr y ( n = nmbr ),measures;characteristic_level,characteristic_level,> nmbr y ( n = nmbr ),characteristic_level
11958,of patients,measures;p-interaction,characteristic_level,of patients,characteristic_level
11975,p valued,arms;measures,characteristic_name,p valued,characteristic_name
11977,tiotropium group ( n = nmbr ),arms;measures,arms,tiotropium group ( n = nmbr ),arms
12058,pfo closure,arms;measures;p-interaction,characteristic_name,pfo closure,characteristic_name
12060,antiplatelet therapy,arms;measures;p-interaction,characteristic_level,antiplatelet therapy,characteristic_level
12062,hazard ratio ( nmbr % cl ),arms;measures;p-interaction,measures,hazard ratio ( nmbr % cl ),measures
12117,exenatide no . of events / total no . ( % ),arms;measures;p-interaction,measures,exenatide no . of events / total no . ( % ),measures
12118,placebo no . of events / total no . ( % ),arms;measures;p-interaction,measures,placebo no . of events / total no . ( % ),measures
12119,hazard ratio ( nmbr % ci ),arms;measures;p-interaction,measures,hazard ratio ( nmbr % ci ),measures
12264,and infusion,arms;measures,characteristic_name,and infusion,characteristic_name
12265,harzard ratio ( nmbr % ci ),arms;measures,measures,harzard ratio ( nmbr % ci ),measures
12268,harzar ratio ( nmbr % ci ),arms;measures,measures,harzar ratio ( nmbr % ci ),measures
